A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy
about
Cancer immunotherapy: how low-level ionizing radiation can play a key role.A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.Fluorescent chemical probes for accurate tumor diagnosis and targeting therapy.Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low ToxicityInfluence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin.Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.Phosphatase-triggered cell-selective release of a Pt(iv)-backboned prodrug-like polymer for an improved therapeutic index.A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
P2860
Q30235014-D0ED915F-783B-4960-A234-7CBF8376050CQ38713515-1B750CF2-C7E5-4B07-B891-5C38A3889A5CQ39187880-E0217065-465F-4134-95E4-89891549A7E9Q41078784-F51B29F7-2284-452A-AD23-BE7CD6225731Q41132341-CC3DA7C7-8AD0-40F1-8A46-AA75680FF137Q41212195-1B65E63E-549B-4BA2-A429-08F782829A2AQ47148105-FA498A3A-D395-4EB7-B7CB-B89363D74062Q48258055-EFE263AC-45F8-4CE5-91A4-01227E674674Q50750601-94AFA856-F6B1-4946-94DA-54D386B6CAD7Q58588998-2C6C073B-B7B2-4D58-A5B6-A8C0FCADA9D6
P2860
A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A Pt(IV) Pro-drug Preferential ...... ian Cancer Immuno-Chemotherapy
@ast
A Pt(IV) Pro-drug Preferential ...... ian Cancer Immuno-Chemotherapy
@en
type
label
A Pt(IV) Pro-drug Preferential ...... ian Cancer Immuno-Chemotherapy
@ast
A Pt(IV) Pro-drug Preferential ...... ian Cancer Immuno-Chemotherapy
@en
prefLabel
A Pt(IV) Pro-drug Preferential ...... ian Cancer Immuno-Chemotherapy
@ast
A Pt(IV) Pro-drug Preferential ...... ian Cancer Immuno-Chemotherapy
@en
P2093
P2860
P356
P1476
A Pt(IV) Pro-drug Preferential ...... ian Cancer Immuno-Chemotherapy
@en
P2093
Michael T Hemann
Samuel G Awuah
Stephen J Lippard
P2860
P304
14854-14857
P356
10.1021/JACS.5B10182
P407
P577
2015-11-12T00:00:00Z